Skip to main content
. Author manuscript; available in PMC: 2012 Dec 1.
Published in final edited form as: Cancer Res. 2011 Sep 21;71(23):7312–7322. doi: 10.1158/0008-5472.CAN-11-1109

Figure 2. Downregulation of activated Src correlates with growth inhibition.

Figure 2

(A) Dasatinib treatment (100 nM) leads to suppression of Src kinase autophosphorylation in cells expressing ZMYM2-FGFR1, CEP110-FGFR1 and BCR-FGFR1. (B) Flow cytometric tracking of cell division with CellTrace™ Violet shows that 72 hours exposure to Dasatinib reduces cell proliferation in cells expressing ZMYM2-FGFR1 but not cells carrying the empty MIEG3 vector or treated with DMSO (vehicle).